low - Clinical trial timelines and FDA review processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital as risk appetite for speculative biotech declines, (2) partnership economics as pharma companies reduce M&A/licensing budgets, (3) post-launch uptake if reproxalap is priced as premium therapy without insurance coverage. Dry eye disease affects 16M+ diagnosed Americans with treatment regardless of economic conditions, providing defensive end-market characteristics once commercialized.

Rising interest rates negatively impact Aldeyra through two channels: (1) Valuation compression - clinical-stage biotechs are long-duration assets (cash flows 3-7+ years out) with high sensitivity to discount rates; 100bps rate increase can justify 15-25% lower NPV in DCF models. (2) Financing costs - while current debt is minimal (Debt/Equity 0.32), higher rates increase dilution required in equity raises as investors demand higher returns, and make convertible debt more expensive. Conversely, falling rates expand valuation multiples for pre-revenue growth stories.

growth/speculative - Aldeyra attracts biotech specialists, event-driven hedge funds, and retail investors seeking asymmetric risk/reward around binary clinical catalysts. The stock appeals to investors comfortable with 50-80% downside risk in exchange for potential 200-500% upside if reproxalap achieves approval and commercial success. Not suitable for income investors (no dividend), value investors (no earnings, high P/B of 6.1x), or risk-averse portfolios. Typical holders include biotech-focused funds (Perceptive Advisors, RTW Investments, Boxer Capital) and momentum traders around data readouts.